Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
The last earnings update was 39 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Moderna. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Moderna's earnings available for a low price, and how does
this compare to other companies in the same industry?
Moderna is not considered high growth as it is expected to be loss making for the next 1-3 years.
Moderna's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Moderna's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Stéphane Bancel serves as Interim President of Valera LLC. Mr. Bancel is Venture Partner of Flagship Pioneering. Mr. Bancel provides strategic counsel and support to portfolio companies at Flagship Pioneering. He serves as the Founding Chief Executive Officer of Moderna Therapeutics, Inc since October 2011. He served as a Senior Advisor of Institut Mérieux SA. He served as the Chief Executive Officer of bioMérieux SA at bioMérieux, Inc. until July 20, 2011. During his five years leading the company, he accelerated the sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. Mr. Bancel served as an Executive Chairman of BG Medicine, Inc from July 2011 to November 1, 2013. From 2000 to 2006, Mr. Bancel worked in the United States, Great Britain and Belgium for Eli Lilly laboratories, where he successively served as Managing Director, Executive Director for Global Manufacturing Strategy, Global Supply Chain and U.S. Distribution and Supply Chain Manager. He served as President of Moderna Therapeutics, Inc. From 1995 to 1998, he worked at bioMérieux, where he was In Charge of the industrial microbiology business for the Asia-Pacific region Sales. He has been a Supervisory Director of Qiagen N.V. since June 26, 2013. He serves as a Director of Moderna Therapeutics, Inc. since March 2011 and Knome, Inc. Mr. Bancel served as the Chairman of BG Medicine, Inc. since November 1, 2013. He served as the Chairman of bioTheranostics, Inc. He served as a Director of Syros Pharmaceuticals, Inc. since November 21, 2013 until June 08, 2017. He served as a Director of Targanta Therapeutics Corp., from August 2008 to February 25, 2009. He served as Director of BG Medicine, Inc. since January 2010. He served as Director of BG Medicine, Inc. from January 2010 to May 12, 2015. He was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best Chief Executive Officer for Investor Relations in France in 2009 and was ranked 1 Chief Executive Officer in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study. He holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in Chemical Engineering from the University of Minnesota and an M.B.A. from Harvard Business School.
Insufficient data for Stéphane to compare compensation growth.
Stéphane's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Moderna management team is over 5 years, this suggests they are a seasoned and experienced team.
CEO & Director
Chief Financial Officer
Chief Accounting Officer
Chief Technical Operations & Quality Officer
Chief Information Officer
Chief Scientific Officer
Investor Relations & Associate Director
General Counsel & Corporate Secretary
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Moderna board of directors is about average.
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.